Evidence map›Paper›PMID 42039433›Full record

ArticlebioRxiv : the preprint server for biology2026

CXCL-CXCR2 signaling drives cancer-endothelium interactions in SCLC metastatic seeding.

Zhang Yang, Andy Xu, Nicholas Hughes, Chien-Wei Peng, Adrienne Visani, Susrutha Puthanmadhom Narayanan, Xue Wen Ng, Isabella Guppy, Chris Roberts, Yaoxuan You and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zhang YangDepartment of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Andy XuDepartment of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-2428-3266
Nicholas HughesDepartment of Genetics, Stanford University, Stanford, CA, USA.
Chien-Wei PengDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Adrienne VisaniDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Susrutha Puthanmadhom NarayananDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Xue Wen NgDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA.
Isabella GuppyDepartment of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Chris RobertsDepartment of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Yaoxuan YouDepartment of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Monte M WinslowDepartment of Genetics, Stanford University, Stanford, CA, USA.
David W PistonDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA.
Jon ParkDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Zhonglin LyuDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Feng ChenDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Li DingDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Rui TangDepartment of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-6950-9580

Funding

WU-SN-TMC Data Analysis CoreU54AG075934 · NIA · WASHINGTON UNIVERSITY · PI FENG CHEN, Li Ding · 2021 to 2026
$8.0M
Human Prostate Tumor Atlas CenterU01CA294532 · NCI · WASHINGTON UNIVERSITY · PI FENG CHEN, Li Ding · 2024 to 2026
$5.3M
Impact of cancer predisposition on oncogenic process, microenvironment, and treatmentR01CA260112 · NCI · WASHINGTON UNIVERSITY · PI FENG CHEN, Li Ding · 2022 to 2026
$2.4M
Dissecting reciprocal interactions between cancer cells and endothelial cells in SCLC liver metastasis.R00CA256039 · NCI · WASHINGTON UNIVERSITY · PI Rui Tang · 2024 to 2026
$743k
Dissecting reciprocal interactions between cancer cells and endothelial cells in SCLC liver metastasis.K99CA256039 · NCI · STANFORD UNIVERSITY · PI TANG, RUI · 2022 to 2023
$312k
NCI NIH HHS K99 CA256039NCI NIH HHS R00 CA256039NCI NIH HHS R01 CA260112NCI NIH HHS U01 CA294532NIA NIH HHS U54 AG075934
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is a highly metastatic malignancy with tropism to the liver, yet the signals that enable organ-specific metastatic colonization remain largely undefined. During metastasis, disseminated cancer cells first encounter endothelial cells (ECs) at the vascular-tissue interface, positioning cancer-endothelium crosstalk as a key determinant of metastatic success. Defining the signaling pathways underlying this reciprocal communication may uncover actionable vulnerabilities for preventing and treating this lethal disease. Here, we uncover an EC-derived CXCL chemokine program that activates cancer-intrinsic CXCR2-RAC1 signaling as a critical mediator of SCLC liver metastasis. By integrating

Identifiers

PMID42039433
PMCPMC13105048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.